ライフサイエンスコーパス: mumps

1 parotitis without laboratory confirmation is mumps.

2 ere high for measles and rubella but low for mumps.

3 rrelation for rubella and no correlation for mumps.

4 ure outbreaks and achieve the elimination of mumps.

5 before the outbreak had an increased risk of mumps.

6 ne-preventable illnesses such as measles and mumps.

7 years for other viruses such as measles and mumps.

8 press memory responses to the recall antigen mumps.

9 opment of prevention and control measures of mumps.

10 as to potential novel strategies to control mumps.

11 ainst measles (1.63 vs 0.78 IU/mL; P = .03), mumps (168 vs 104 RU/mL; P = .03), and rubella (69 vs 45

12 varicella (14.0 days), smallpox (17.7 days), mumps (18.0 days), rubella (18.3 days), and pertussis (2

13 MuV-IA led to the typical clinical signs of mumps 2 weeks to 4 weeks postinfection.

14 hort: 3.3 months for measles, 2.7 months for mumps, 3.9 months for rubella, and 3.4 months for varice

15 ols (measles, 100% vs 92% [95% CI, 84%-99%]; mumps, 97% [95% CI, 95%-100%] vs 81% [95% CI, 72%-93%];

16 ary and epidemiological dynamics of measles, mumps and canine distemper viruses.

17 together with functionally active "headless" mumps and Newcastle disease virus HN proteins, provide i

18 tion to live-virus vaccines such as measles, mumps and rubella (MMR) vaccination.

19 t a serious adverse event following measles, mumps and rubella (MMR) vaccination.

20 iseases, including smallpox, polio, measles, mumps and yellow fever.

21 ficity by using either live viruses (dengue, mumps, and measles viruses) or nucleic acid material (Ni

22 tures of homologous proteins in the measles, mumps, and Nipah viruses.

23 y index decreased by 8% for measles, 24% for mumps, and remained unchanged for rubella.

24 e average population immunities for measles, mumps, and rubella (92%, 87%, 92%) were similar to the p

25 (PHIV) may not be protected against measles, mumps, and rubella (MMR) because of impaired initial vac

26 esitancy, using the case example of measles, mumps, and rubella (MMR) vaccination and measles.

27 Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective again

28 Routinely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 mon

29 The combined measles, mumps, and rubella (MMR) vaccine has been successfully a

30 ted data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults.

31 m children 6 weeks after receipt of measles, mumps, and rubella (MMR) vaccine were tested for the abi

32 ad received one or two doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with m

33 (SA-14-14-2), varicella (Varivax), measles, mumps, and rubella (MMR-II), measles (Attenuvax), rubell

34 neffects (negative controls) of the measles, mumps, and rubella and measles, mumps, rubella, and vari

35 ed with the separately administered measles, mumps, and rubella and varicella vaccines.

36 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG)

37 the risk of seizures compared with measles, mumps, and rubella vaccine administered with or without

38 n participants who were vaccinated (measles, mumps, and rubella vaccine/tick-borne encephalitis vacci

39 mount of circulating antibodies for measles, mumps, and rubella was measured with enzyme immunoassays

40 pertussis, measles and rubella, or measles, mumps, and rubella) during pregnancy, confirming the fin

41 (Attenuvax) at 6 months of age and measles, mumps, and rubella, live attenuated (MMRII) vaccine at 1

42 Influenza, measles, mumps, and rubella, varicella, hepatitis A, meningococca

43 nfections per infectious person for measles, mumps, and rubella.

44 odominant protein), tetanus toxoid, measles, mumps, and rubella.

45 ses, we compared vaccine-induced preoutbreak mumps antibody levels between individuals who developed

46 ase patients generally had lower preoutbreak mumps antibody levels than nonpatients.

47 Mumps antibody levels were evaluated by plaque-reduction

48 The mumps antibody response to MMR2 was vigorous, but over a

49 concentrations from cultures stimulated with mumps antigen were higher in naturally immune adults tha

50 The responses of RA lymphocytes to mumps antigen were significantly lower that those in con

51 h-income countries since the introduction of mumps antigen-containing vaccines.

52 Complications of mumps can include meningitis, deafness, pancreatitis, or

53 Mumps case investigations included patient interviews, m

54 umps incidence by more than 99% and kept the mumps case numbers as low as hundreds of cases per year

55 verlapped and no cutoff points separated all mumps case patients from all nonpatients.

56 ody levels between individuals who developed mumps (case patients) and those who did not develop mump

57 We examined national data on mumps cases reported during 2006, detailed case data fro

58 rive held on campus before identification of mumps cases, we compared vaccine-induced preoutbreak mum

59 was followed by historically low reports of mumps cases.

60 t mumps virus has been effective in reducing mumps cases.

61 Fifty-four (96%) cases had received >/=1 mumps-containing vaccine, 1 (2%) was unvaccinated due to

62 spite a high coverage rate with two doses of mumps-containing vaccine, a large mumps outbreak occurre

63 , 89% had previously received two doses of a mumps-containing vaccine, and 8% had received one dose.

64 human and wildlife populations: measles and mumps continue to affect the health of children worldwid

65 For mumps control, high vaccine coverage and high population

66 a multiplex real-time RT-PCR assay for rapid mumps diagnosis in a clinical setting.

67 ts from viral culture, the gold standard for mumps diagnostic testing.

68 97% (from 0.32 to 0.009) and admissions for mumps encephalitis decreased by 98% (from 0.60 to 0.01)

69 Admissions for measles and mumps encephalitis have decreased substantially.

70 1 case patients, 22 nonpatients who reported mumps exposure but no mumps symptoms, and 103 nonpatient

71 The incidence of mumps has declined dramatically in high-income countries

72 kenpox, shingles, cold sores, mononucleosis, mumps, hepatitis B, plantar warts, positive tuberculosis

73 tudents had more than nine times the risk of mumps if they had received the second MMR dose 13 years

74 All adults were positive for mumps IgG.

75 of the 44 (5%) cases tested by serology were mumps IgM positive, and 27 of the 40 (68%) tested by RT-

76 Mumps IgM was detected in 17% of available specimens.

77 udy was to evaluate the short- and long-term mumps immunogenicity of MMR2.

78 niversity students and staff were tested for mumps immunoglobulin (Ig) G by enzyme immunoassay (EIA).

79 proliferative and flow cytometry assays, and mumps immunoglobulin (Ig) G was measured using enzyme-li

80 Mumps immunoglobulin M (IgM) testing was negative and re

81 uating cell-mediated and humoral immunity to mumps in 10 vaccinated and 10 naturally immune adults.

82 However, recent large outbreaks of mumps in highly vaccinated populations suggest waning of

83 cination had reduced the annual incidence of mumps in the United States by more than 99%, with few ou

84 program implemented since the 1960s reduced mumps incidence by more than 99% and kept the mumps case

85 Widespread mumps vaccination has reduced mumps incidence dramatically; however, outbreaks still o

86 Mumps incidence in mainland China remains at a high leve

87 rubella induced high-avidity antibodies and mumps induced low-avidity antibodies after both vaccinat

88 Laboratory confirmation of mumps infection can be made by the detection of immunogl

89 vivirus NS5 protein or by YFV infection, and mumps infection did not alter CD4 mRNA or protein levels

90 Mumps infection results in an acute illness with symptom

91 ed a molecular method for rapidly diagnosing mumps infection that may be used to complement existing

92 f antibodies might contribute to measles and mumps infections in twice-MMR-vaccinated individuals.

93 Mumps is a highly contagious human disease, characterize

94 Mumps is a potentially severe viral infection.

95 human viral infections, such as measles and mumps, may have their ancestry traced back to bats.

96 posure immunization with vaccines to prevent mumps, measles, rubella, varicella, pertussis, hepatitis

97 No laboratory-confirmed cases of mumps meningitis were detected among children aged 12-23

98 confidence limit excluded the risk found for mumps meningitis with Urabe vaccines (1:143,000 doses).

99 lymphocytic choriomeningitis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respir

100 case patients) and those who did not develop mumps (nonpatients).

101 Abs did not neutralize or immune-precipitate mumps or yellow fever viruses.

102 inister a third dose of MMR vaccine improved mumps outbreak control and that waning immunity probably

103 mps virus RNA detection was studied during a mumps outbreak in a highly vaccinated university populat

104 -rubella-varicella vaccination, and the 2006 mumps outbreak in the American Midwest.

105 inated young adults reported during the 2006 mumps outbreak in the United States heightened concerns

106 In 2006, the largest mumps outbreak in the United States in 20 years occurred

107 In a mumps outbreak in the United States, many infected indiv

108 oal was established, but in 2006 the largest mumps outbreak in two decades occurred in the United Sta

109 es-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown.

110 However, a large mumps outbreak occurred in vaccinated populations in 200

111 In 2006, a mumps outbreak occurred on a university campus despite >

112 o doses of mumps-containing vaccine, a large mumps outbreak occurred, characterized by two-dose vacci

113 notype G wild-type virus obtained during the mumps outbreak that occurred in the United States in 200

114 Mumps outbreaks can occur in highly vaccinated populatio

115 In recent years, many mumps outbreaks have occurred in vaccinated populations

116 Recently, numerous large-scale mumps outbreaks have occurred in vaccinated populations.

117 Recent mumps outbreaks in older vaccinated populations were cau

118 future years signal an increased risk of new mumps outbreaks.

119 reby reducing the risk of future large-scale mumps outbreaks.

120 ular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses.

121 G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens.

122 ended before 1980 were shown for diphtheria, mumps, pertussis, and tetanus.

123 Admissions for mumps-related meningitis almost disappeared following in

124 pertussis, tetanus, poliomyelitis, measles, mumps, rubella (including congenital rubella syndrome),

125 considered eligible to receive the measles, mumps, rubella (MMR) vaccine.

126 e, thimerosal, and/or receiving the measles, mumps, rubella (MMR) vaccine.

127 an 90% of all school types required measles, mumps, rubella, and hepatitis B vaccines for entering st

128 A quadrivalent vaccine combining measles, mumps, rubella, and varicella antigens (MMRV) was develo

129 rsely, completion by age 2 years of measles, mumps, rubella, and varicella immunization may offer imp

130 The combination measles, mumps, rubella, and varicella vaccine is associated with

131 In the analysis of vaccine type, measles, mumps, rubella, and varicella vaccine was associated wit

132 the measles, mumps, and rubella and measles, mumps, rubella, and varicella vaccines among children wh

133 sonnel, including students, receive measles, mumps, rubella, hepatitis B, varicella, influenza, and p

134 cific for viral antigens (vaccinia, measles, mumps, rubella, varicella-zoster virus, and Epstein-Barr

135 I) of FSs in toddlers given MMRV and measles-mumps-rubella (MMR) and a national cohort study of vacci

136 ty of a 2-dose pediatric schedule of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (

137 and Prevention and data on national measles-mumps-rubella (MMR) vaccination coverage during postelim

138 Measles-mumps-rubella (MMR) vaccination coverage with at least a

139 y and the effects of live attenuated measles-mumps-rubella (MMR) vaccination on disease activity in p

140 To protect young infants, measles-mumps-rubella (MMR) vaccination was offered to those age

141 combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 year

142 n to introduction of PCR testing and measles-mumps-rubella (MMR) vaccination.

143 Measles-mumps-rubella (MMR) vaccinations have been offered to Fi

144 research showing no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorder

145 peared following introduction of the measles-mumps-rubella (MMR) vaccine in 1988.

146 ose of measles vaccine as a combined measles-mumps-rubella (MMR) vaccine in 1999 and the implementati

147 The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak

148 The measles-mumps-rubella (MMR) vaccine is effective in eliciting a

149 Primate schedule with or without the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and t

150 coverage of students with 2 doses of measles-mumps-rubella (MMR) vaccine.

151 Measles-mumps-rubella (MMR) vaccines containing the Urabe strain

152 asles vaccine at 6 months of age and measles-mumps-rubella (MMR)-II at 12 months of age (n=26), measl

153 asles vaccine at 9 months of age and measles-mumps-rubella (MMR)-II at 12 months of age (n=48), or on

154 ella-varicella vaccine over separate measles-mumps-rubella and varicella administration.

155 Measles-mumps-rubella dose 1 vaccination coverage ranged from 97

156 ve been reported with events such as measles-mumps-rubella immunization, large-scale studies have not

157 opies/mL, CD4% >/=15, and >/=1 prior measles-mumps-rubella vaccination (MMR) were given another MMR.

158 Widespread avoidance of Measles-Mumps-Rubella vaccination (MMR), with a consequent incre

159 ositive for measles and rubella; and measles-mumps-rubella vaccination coverage levels.

160 Typhoid or measles-mumps-rubella vaccination was associated with lower anti

161 tates have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.

162 ldren have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.

163 by EIA were offered a third dose of measles-mumps-rubella vaccine (MMR3), and serum specimens were o

164 sles vaccine to the incorporation of measles-mumps-rubella vaccine administered in the routine progra

165 collected and geocoded tweets about measles-mumps-rubella vaccine and classified their sentiment usi

166 mice exposed to the live-attenuated measles-mumps-rubella vaccine regardless of route of administrat

167 and -negative adults immunized with measles-mumps-rubella vaccine were studied.

168 tory of vaccination with >2 doses of measles-mumps-rubella vaccine.

169 lymphoproliferative responses after measles-mumps-rubella-II (MMR-II) vaccination, in a population-b

170 We genotyped 118 measles-mumps-rubella-vaccinated subjects for SNPs from 6 cytoki

171 le of measles-mumps-rubella (MMR) or measles-mumps-rubella-varicella (MMRV) vaccine was assessed in c

172 ng combination vaccines, such as the measles-mumps-rubella-varicella (MMRV) vaccine, into immunizatio

173 iae, febrile seizure rates following measles-mumps-rubella-varicella vaccination, and the 2006 mumps

174 lent varicella vaccine or a combined measles-mumps-rubella-varicella vaccine (MMRV).

175 rence for the use of the combination measles-mumps-rubella-varicella vaccine over separate measles-mu

176 same time, licensure of the combined measles-mumps-rubella-varicella vaccine was completed, which all

177 fever, varicella-zoster, multivalent measles/mumps/rubella, and two rotavirus live vaccines were part

178 rds review, and laboratory testing including mumps serology and RT-PCR.

179 t no such international reference exists for mumps serology.

180 CI, 60%-70%] vs 98% [95% CI, 95%-100%]), and mumps seropositivity (59% [95% CI, 55%-64%] vs 97% [95%

181 ization assay and rubella seroprotection and mumps seropositivity by enzyme immunoassay.

182 Predictors of rubella seroprotection and mumps seropositivity were similar.

183 To understand prior mumps seroprevalence and factors associated with the pre

184 outbreak potential, demonstrated using 2006 mumps seroprevalence data from Belgium and Belgian vacci

185 ide primers and a TaqMan probe targeting the mumps SH gene, as well as primers and a probe that targe

186 Mumps should be considered in patients with parotitis re

187 The mean percentages of mumps-specific CD4+ T cells that expressed CD69 and prod

188 Protein sequences of measles- and mumps-specific circulating antibodies were encoded for b

189 Mumps-specific T cell activation and interferon (IFN)-ga

190 npatients who reported mumps exposure but no mumps symptoms, and 103 nonpatients who reported no know

191 hird dose of MMR vaccine had a lower risk of mumps than did those who had received two doses, after a

192 se was associated with a 78.1% lower risk of mumps than receipt of a second dose (adjusted hazard rat

193 is B vaccine (HBV), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus influenza t

194 quire STAT2 to recruit the STAT1 target, yet mumps V protein binds STAT3 independent of STAT1 and STA

195 SV5 and mumps V proteins require STAT2 to recruit the STAT1 targ

196 the outbreak, national coverage of one-dose mumps vaccination among preschoolers was 89% or more nat

197 Widespread mumps vaccination has reduced mumps incidence dramatical

198 A mumps vaccination program implemented since the 1960s re

199 The widespread use of a second dose of mumps vaccine among U.S. schoolchildren beginning in 199

200 icating that it is a promising candidate for mumps vaccine development.

201 esponses in human serum samples from the pre-mumps vaccine era.

202 United States heightened concerns regarding mumps vaccine failure.

203 The persistence of cellular immunity to mumps vaccine has not been defined.

204 A more effective mumps vaccine or changes in vaccine policy may be needed

205 euroattenuation and neurovirulence, ensuring mumps vaccine safety has proven problematic, as demonstr

206 induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralized the outbrea

207 uals were adults who had received 2 doses of mumps vaccine.

208 of 18 and 24 years had received two doses of mumps vaccine.

209 ing of virus seeds used in the production of mumps vaccines.

210 Mumps viral antigen was detected in parotid glands by im

211 luate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps vi

212 Here we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) a

213 Here we report that while PIV2, PIV5, and mumps virus (MuV) are sensitive to IFIT1, nonrubulavirus

214 Mumps virus (MuV) causes an acute infection in humans ch

215 The mumps virus (MuV) genome encodes a phosphoprotein (P) th

216 otype F has been the predominant genotype of mumps virus (MuV) in the last 20 years in mainland China

217 Mumps virus (MuV) infection may cause serious diseases i

218 Mumps virus (MuV) is a highly contagious pathogen, and d

219 Mumps virus (MuV) is a reemerging paramyxovirus that cau

220 Mumps virus (MuV) is highly neurotropic and was the lead

221 We systematically mapped the domains in mumps virus (MuV) P and investigated their interactions

222 iral proteins play in the phosphorylation of mumps virus (MuV) P.

223 To define mumps virus (MuV) proteins important for this process, v

224 To investigate the role of the mumps virus (MuV) SH protein in virulence, multiple stop

225 with high phylogenetic relatedness to human mumps virus (MuV) was identified recently at the nucleic

226 Mumps virus (MuV), a paramyxovirus containing a negative

227 The nucleocapsid protein (NP) of mumps virus (MuV), a paramyxovirus, was coexpressed with

228 Mumps virus (MuV), a rubulavirus of the paramyxovirus fa

229 luenza virus 3 (HPIV3), measles virus (MeV), mumps virus (MuV), and respiratory syncytial virus (RSV)

230 esults were obtained for the closely related mumps virus (MuV), except that MuV particles derived fro

231 RNA-mediated signaling; these are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2),

232 breaks and to understand the pathogenesis of mumps virus (MuV).

233 ps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearin

234 ative responses to measles virus (P=.01) and mumps virus (P=.006).

235 scribe the generation of a novel recombinant mumps virus (rMuV) expressing HIV-1 Gag (rMuVgag) and me

236 proteins of Nipah virus, measles virus, and mumps virus also abolishes MDA5 interaction.

237 mber of cellular genes compared to wild-type mumps virus and increases cell death in infected cells,

238 l culture, or by detection of the RNA of the mumps virus by reverse transcription (RT)-PCR.

239 A recombinant mumps virus carrying the E95D mutation in its P and V pr

240 e-adjusted seroprevalence of IgG antibody to mumps virus during 1999-2004 was 90.0% (95% CI, 88.8%-91

241 on of three animal models with an isolate of mumps virus from a recent outbreak (MuV-IA).

242 Vaccination against mumps virus has been effective in reducing mumps cases.

243 Anti-mumps virus immunoglobulin M (IgM) antibodies were detec

244 n of immunoglobulin M-specific antibodies to mumps virus in acute-phase serum samples, the isolation

245 acute-phase serum samples, the isolation of mumps virus in cell culture, or by detection of the RNA

246 developed to allow rapid characterization of mumps virus in clinical samples.

247 The mumps virus is a negative-strand RNA virus in the family

248 pinal fluid (CSF) samples and in extracts of mumps virus isolates from patients with various clinical

249 uently, PIV5 NP protein is incompatible with mumps virus M protein.

250 that interactions between this region of the mumps virus NP and its polymerase leads to exposure of t

251 Mumps virus NP protein harbors DWD in place of the DLD s

252 The structure of an empty mumps virus nucleocapsid-like particle is determined to

253 esent the best animal model for the study of mumps virus pathogenesis.

254 The duration of mumps virus RNA detection was studied during a mumps out

255 Mumps virus RNA was characterized directly from cerebros

256 ble EIA kits were used to evaluate wild-type mumps virus serological responses in human serum samples

257 The study also allowed characterization of mumps virus strains from Argentina as part of a new subg

258 accine viruses, raising concern that certain mumps virus strains may escape vaccine-induced immunity.

259 efully selected group of genetically diverse mumps virus strains.

260 te among the relative neurovirulent risks of mumps virus strains.

261 man parainfluenza virus 2 targets STAT2, and mumps virus targets both STAT1 and STAT3.

262 interferon-activated STAT1 or STAT2 protein, mumps virus V protein is unique in its ability to also t

263 that a single amino acid substitution in the mumps virus V protein, E95D, results in defective STAT3

264 ples to neutralize the genotype A Jeryl Lynn mumps virus vaccine strain and a genotype G wild-type vi

265 In contrast, mumps virus was not inhibited by the expression of flavi

266 to affect attenuation were detected in OPV, mumps virus, and varicella-zoster virus.

267 associated with the presence of antibody to mumps virus, data from the 1999-2004 National Health and

268 Mumps virus, enteroviruses (including human parechovirus

269 , parainfluenza virus type 5, measles virus, mumps virus, Hendra virus, and Nipah virus.

270 ramyxovirus pathogens include measles virus, mumps virus, human respiratory syncytial virus, and the

271 Mumps virus, like other paramyxoviruses in the Rubulavir

272 myxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP interaction also contributes to effici

273 virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyssavirus, herpes simplex v

274 oteins of the paramyxoviruses measles virus, mumps virus, Newcastle disease virus, human parainfluenz

275 samples were seropositive for measles virus, mumps virus, or rubella virus antibodies, and there were

276 important viruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytia

277 predict genes for 12 viruses: measles virus, mumps virus, rubella virus, respiratory syncytial virus,

278 Mumps virus-neutralizing antibodies are believed to be t

279 Moreover, since mumps virus-specific antibody titers are generally low i

280 A mumps virus-specific enzyme immunoassay was used to meas

281 A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated

282 tly assesses the neurovirulence potential of mumps viruses in humans and is robust and reproducible.

283 Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein a

284 hown that clinical isolate-based recombinant mumps viruses lacking expression of either the V protein

285 ic and neurovirulent properties of wild-type mumps viruses, most national regulatory organizations re

286 d have reduced efficacy against heterologous mumps viruses.

287 shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus.

288 machinery in VLP budding was obtained, with mumps VLP production inhibited upon expression of domina

289 Efficient production of mumps VLPs occurred only when the M protein was coexpres

290 proteins and allowed efficient production of mumps VLPs.

291 The national incidence of mumps was 2.2 per 100,000, with the highest incidence am

292 T and B cell immunity to mumps was detected in adults at least 10 years after imm

293 enrolled during the 2015-2016 academic year, mumps was diagnosed in 259 students.

294 T cell immunity to mumps was high in both groups; 70% of vaccinated and 80%

295 Fifty-six NYC residents with mumps were identified with onset between 12 January and

296 nd other symptoms clinically compatible with mumps were investigated, and demographic, clinical, labo

297 A total of 6584 cases of mumps were reported in 2006, with 76% occurring between

298 0, a total of 3502 outbreak-related cases of mumps were reported in New York City, two upstate New Yo

299 MMR) vaccines containing the Urabe strain of mumps were withdrawn in the United Kingdom in 1992 follo

300 ses of parotitis are generally assumed to be mumps, which often requires a resource-intensive public